Featured Stories
J&J Expects Persistent Pricing Pressure Into 2019
CEO Alex Gorsky highlighted growing public concern over US drug costs during J&J's Q4 earnings call, pressing for more transparency and value-based health care. The company's net drug prices declined more than 6% in 2018, he added.
Full Steam Ahead At Ferring To Unlock Microbiome Potential For Reproduction
The Swiss group is expanding its alliance with the Karolinska Institutet to conduct 10 studies designed to improve understanding of the microbiome’s impact on reproductive and gut health challenges.
Q4 Pharma Earnings Preview: J&J, Bristol And AbbVie
Johnson & Johnson has solid growth drivers in pharmaceuticals, but still faces an overhang related to talc controversy; Bristol's call will be dominated by the just-announced Celgene acquisition; and AbbVie will face questions about its cancer plans after expensive failure with Rova-T.
Latest News
Recent Tweets from ScripFactoring the "What Ifs" into Supply Forecasting
With the pressure on to deliver new products faster and more efficiently, sponsors are facing a variety of challenges. Download this whitepaper and discover the challenges as well as aspects to consider when developing a supply plan, the influence of early decisions and much more.
Pharma Report Store
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now:
Commercial Explore this Topic
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Sun Firefights Governance Concerns
Sun has promised to implement certain changes to address corporate governance concerns that have riled investors, including “unwinding” a loan transaction and doing away with a controversial related party arrangement for domestic sales. But will that be enough for markets to "forget" allegations of lapses or "re-rate" the firm any time soon?
Biotech Showcase 2019: Mimicking plants creates GI infection antibiotic alternative
Gastrointestinal infections are the number one reason for US physician visits and account for about half the $50bn in global antibiotic sales. Speaking during Biotech Showcase 2019, Alex Huang, CEO of Quellthera, described to Mike Ward how the company is developing a novel prodrug concept, which mimics plant hypersensitive responses to toxins, as a sustainable alternative to antibiotics and as an adjunctive therapy to standard of care antibiotics for treatment and prophylaxis for a range of GI infections.
GSK Looks For New Chair To Lead It Through New Strategic Direction
GSK’s non-exec chairman steps down from the UK firm, just a month after announcing a split that will reshape the company.
Molecule Diversity Creates Developmental Challenges For Aspiring Commercial Biotechs
Speaking on the sidelines at BIO-Europe 2018, Jenifer Wheat, head of commercial development at Lonza’s mammalian and microbial MMBU, explains to Scrip how having a manufacturing component in their commercialization strategies can facilitate success. Even those companies not planning to launch their own products but planning to license programs to partners can benefit from support from the contract development manufacturing sector.
Deal Watch: Celgene Makes Alliances With Kyn, Obsidian After Bristol Buyout
Just two weeks after agreeing on a merger with Bristol, Celgene is back at its own deal-making, signing cancer-focused R&D pacts with Kyn and Obsidian. Boehringer and Bioharmony collaborate on novel therapies for hospital-acquired infections, while Sanofi teams with Biomunex on bi- and multi-specific antibodies.
Aum Bets On Asia-To-Global Oncology Model
Dark Days For Sun As Governance Saga Escalates
Allegations of corporate governance lapses continued to singe Sun, but there is little clarity on which way things are headed, at least for now.
Catalan Biotechs Boosted By International Backers
The number of foreign investors participating in Catalan biotech companies has gone from 0 to 50, and over the past five years alone, the figure has increased tenfold, according to the latest Biocat report.
Policy & Regulation Explore this Topic
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Rare But Real: How One Startup Is Willing Itself To Lift China Orphan Drug Market
As a promising market for orphan drugs, China has seen several approvals in this space in the past six months, mostly from multinationals. But Beijing-based CANbridge believes that a smaller biotech also has a good shot at a leadership role, despite a lack of funding and reimbursement and prickly pricing issues.
Financial Transparency Concerns Over Patient Groups Advising NICE
England and Wales' cost-effectiveness agency has been urged to review its disclosure policy in a BMJ report which calls on NICE to probe the financial transparency of patient organizations that contribute to reimbursement assessments.
Pharma Industry Holds Tight As Disorderly Brexit Approaches
A worst-case Brexit scenario – a disorderly one – has become more likely, making an already white-knuckled life sciences industry step up its preparations.
Scrip Asks...What Does 2019 Hold For Biopharma? Part 3: Pricing, Reimbursement And Market Access
How much therapies should cost and how they should be reimbursed are questions that are expected to dominate in 2019, according to industry experts and participants surveyed by Scrip on their expectations for the coming year. This is the focus for the final installment of our three-part Scrip Asks series.
Research & Development Explore this Topic
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Aurinia’s Voclosporin Misses Superior Tolerability Vs. Restasis, But Pushes On In Drug Eye
Aurinia's voclosporin missed the primary endpoint of superior tolerability compared to Restasis, but hit objective secondary efficacy endpoints that that may better position it for approval in dry eye.
Bone Therapeutics Cracks On With Allogeneic Cells For Spinal Fusion, Broken Bones
2019 should see top-line clinical results for Bone Therapeutics' off-the-shelf cell therapy for spinal fusion procedures.
TaiwanJ To Progress Liver Drug JKB-122 In AIH After Good Phase II Data
Taiwanese speciality pharma TaiwanJ said its Phase II orphan drug designation study of investigational therapy JKB-122 in autoimmune hepatitis met both the primary and secondary endpoints.
Revamped Redx’s New CEO Says Porcupine Inhibitor Trials 'Now On Track'
After regulatory talks, revamped Redx gets green light to resume clinical study of RXC004 in patients with advanced solid tumors, while sister porcupine inhibitor RXC006 is set to enter IPF trials in 2020, the biotech's CEO tells Scrip.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.